BACKGROUND: Patients with homozygous familial hypercholesterolaemia respond inadequately to existing drugs. We aimed to assess the efficacy and safety of the microsomal triglyceride transfer protein inhibitor lomitapide in adults with this disease. METHODS: We did a single-arm, open-label, phase 3 study of lomitapide for treatment of patients with homozygous familial hypercholesterolemia. Current lipid lowering therapy was maintained from 6 weeks before baseline through to at least week 26. Lomitapide dose was escalated on the basis of safety and tolerability from 5 mg to a maximum of 60 mg a day. The primary endpoint was mean percent change in levels of LDL cholesterol from baseline to week 26, after which patients remained on lomitapide through to week 78 for safety assessment. Percent change from baseline to week 26 was assessed with a mixed linear model. FINDINGS: 29 men and women with homozygous familial hypercholesterolaemia, aged 18 years or older, were recruited from 11 centres in four countries (USA, Canada, South Africa, and Italy). 23 of 29 enrolled patients completed both the efficacy phase (26 weeks) and the full study (78 weeks). The median dose of lomitapide was 40 mg a day. LDL cholesterol was reduced by 50% (95% CI -62 to -39) from baseline (mean 8·7 mmol/L [SD 2·9]) to week 26 (4·3 mmol/L [2·5]; p<0·0001). Levels of LDL cholesterol were lower than 2·6 mmol/L in eight patients at 26 weeks. Concentrations of LDL cholesterol remained reduced by 44% (95% CI -57 to -31; p<0·0001) at week 56 and 38% (-52 to -24; p<0·0001) at week 78. Gastrointestinal symptoms were the most common adverse event. Four patients had aminotransaminase levels of more than five times the upper limit of normal, which resolved after dose reduction or temporary interruption of lomitapide. No patient permanently discontinued treatment because of liver abnormalities. INTERPRETATION: Our study suggests that treatment with lomitapide could be a valuable drug in the management of homozygous familial hypercholesterolaemia. FUNDING: FDA Office of the Orphan Product Development, Aegerion Pharmaceuticals.
BACKGROUND:Patients with homozygous familial hypercholesterolaemia respond inadequately to existing drugs. We aimed to assess the efficacy and safety of the microsomal triglyceride transfer protein inhibitor lomitapide in adults with this disease. METHODS: We did a single-arm, open-label, phase 3 study of lomitapide for treatment of patients with homozygous familial hypercholesterolemia. Current lipid lowering therapy was maintained from 6 weeks before baseline through to at least week 26. Lomitapide dose was escalated on the basis of safety and tolerability from 5 mg to a maximum of 60 mg a day. The primary endpoint was mean percent change in levels of LDL cholesterol from baseline to week 26, after which patients remained on lomitapide through to week 78 for safety assessment. Percent change from baseline to week 26 was assessed with a mixed linear model. FINDINGS: 29 men and women with homozygous familial hypercholesterolaemia, aged 18 years or older, were recruited from 11 centres in four countries (USA, Canada, South Africa, and Italy). 23 of 29 enrolled patients completed both the efficacy phase (26 weeks) and the full study (78 weeks). The median dose of lomitapide was 40 mg a day. LDL cholesterol was reduced by 50% (95% CI -62 to -39) from baseline (mean 8·7 mmol/L [SD 2·9]) to week 26 (4·3 mmol/L [2·5]; p<0·0001). Levels of LDL cholesterol were lower than 2·6 mmol/L in eight patients at 26 weeks. Concentrations of LDL cholesterol remained reduced by 44% (95% CI -57 to -31; p<0·0001) at week 56 and 38% (-52 to -24; p<0·0001) at week 78. Gastrointestinal symptoms were the most common adverse event. Four patients had aminotransaminase levels of more than five times the upper limit of normal, which resolved after dose reduction or temporary interruption of lomitapide. No patient permanently discontinued treatment because of liver abnormalities. INTERPRETATION: Our study suggests that treatment with lomitapide could be a valuable drug in the management of homozygous familial hypercholesterolaemia. FUNDING: FDA Office of the Orphan Product Development, Aegerion Pharmaceuticals.
Authors: Gilbert R Thompson; M Barbir; D Davies; P Dobral; M Gesinde; M Livingston; P Mandry; A D Marais; S Matthews; C Neuwirth; A Pottle; C le Roux; D Scullard; C Tyler; S Watkins Journal: Atherosclerosis Date: 2009-06-18 Impact factor: 5.162
Authors: Frederick J Raal; Gillian J Pilcher; Vanessa R Panz; Hendrick E van Deventer; Brigitte C Brice; Dirk J Blom; A David Marais Journal: Circulation Date: 2011-10-10 Impact factor: 29.690
Authors: Frederick J Raal; Raul D Santos; Dirk J Blom; A David Marais; Min-Ji Charng; William C Cromwell; Robin H Lachmann; Daniel Gaudet; Ju L Tan; Scott Chasan-Taber; Diane L Tribble; Joann D Flaim; Stanley T Crooke Journal: Lancet Date: 2010-03-20 Impact factor: 79.321
Authors: Gilbert R Thompson; Alberico Catapano; Samir Saheb; Marielle Atassi-Dumont; Mahmoud Barbir; Mats Eriksson; Bernhard Paulweber; Eric Sijbrands; Anton F Stalenhoef; Klaus G Parhofer Journal: Curr Opin Lipidol Date: 2010-12 Impact factor: 4.776
Authors: C Stefanutti; G D'Alessandri; G Russi; G De Silvestro; M G Zenti; P Marson; D Belotherkovsky; A Vivenzio; S Di Giacomo Journal: Atheroscler Suppl Date: 2009-12-29 Impact factor: 3.235
Authors: A David Marais; Frederick J Raal; Evan A Stein; Daniel J Rader; James Blasetto; Michael Palmer; Wim Wilpshaar Journal: Atherosclerosis Date: 2007-08-28 Impact factor: 5.162
Authors: Frederick F Samaha; James McKenney; Leanne T Bloedon; William J Sasiela; Daniel J Rader Journal: Nat Clin Pract Cardiovasc Med Date: 2008-05-27
Authors: Daniel M Kolansky; Marina Cuchel; Bernard J Clark; Steve Paridon; Brian W McCrindle; Susan E Wiegers; Luis Araujo; Yogesh Vohra; Joep C Defesche; James M Wilson; Daniel J Rader Journal: Am J Cardiol Date: 2008-09-11 Impact factor: 2.778